Education
About Us
Working with TipRanks
Follow Us
Natera (NTRA)
NASDAQ:NTRA
NTRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$92.14 - $183.00
Previous CloseN/A
Volume352.74K
Average Volume (3M)1.46M
Market Cap
$20.60B
Enterprise ValueN/A
Total Cash (Recent Filing)$968.28M
Total Debt (Recent Filing)$187.12M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Jul 31, 2025EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding135,539,900
10 Day Avg. Volume1,540,802
30 Day Avg. Volume1,461,549
Financial Highlights & Ratios
PEG Ratio-7.33
Price to Book (P/B)15.82
Price to Sales (P/S)0.00
P/FCF Ratio281.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$203.23Price Target Upside29.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionNatera's continued data generation and international expansion should enable the company to expand its leadership position in minimal residual disease testing.
Market PositionNTRA remains a growth story with its leading MRD franchise serving an underpenetrated $20B market and a strong base with leadership positions in NIPT and carrier screening.
Revenue GrowthThe company increased its 2025 revenue guidance to between $1.94 billion and $2.02 billion, reflecting about 26% year-over-year growth at the midpoint.
Bears Say
Operating ExpensesThere was a modest increase in operating expenses to drive future growth, which was higher than initial forecasts.
Profitability ConcernsOperating leverage was deferred, which may impact short-term profitability despite the positive outlook.
Regulatory ApprovalNatera elaborated on its progress toward Pharmaceuticals and Medical Devices Agency approval of Signatera in Japan, expected late 2025 or early 2026.
---
Ownership Overview
4.82% Insiders
27.73% Mutual Funds
0.42% Other Institutional Investors
48.51% Public Companies and
Individual Investors
NTRA FAQ
What was Natera’s price range in the past 12 months?
Natera lowest stock price was $92.14 and its highest was $183.00 in the past 12 months.
What is Natera’s market cap?
Natera’s market cap is $20.60B.
When is Natera’s upcoming earnings report date?
Natera’s upcoming earnings report date is Jul 31, 2025 which is in 78 days.
How were Natera’s earnings last quarter?
Natera released its earnings results on May 08, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.64 by $0.14.
Is Natera overvalued?
According to Wall Street analysts Natera’s price is currently Undervalued.
Does Natera pay dividends?
Natera does not currently pay dividends.
What is Natera’s EPS estimate?
Natera’s EPS estimate is -0.61.
How many shares outstanding does Natera have?
Natera has 135,539,900 shares outstanding.
What happened to Natera’s price movement after its last earnings report?
Natera reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.64. Following the earnings report the stock price went down -6.533%.
Which hedge fund is a major shareholder of Natera?
Currently, no hedge funds are holding shares in NTRA
---
Natera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$203.23 (29.21% Upside)
$203.23 (29.21% Upside)
Blogger Sentiment
Bullish
NTRA Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 23.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.38%
12-Months-Change
Fundamentals
Return on Equity
-18.66%
Trailing 12-Months
Asset Growth
17.99%
Trailing 12-Months
Company Description
Natera
Natera, Inc. (NTRA) is a global leader in cell-free DNA testing, specializing in genetic testing services that focus on women's health, oncology, and organ health. The company utilizes proprietary technology to develop and commercialize non-invasive tests that help in early detection and management of genetic conditions. Natera's flagship products include Panorama, a non-invasive prenatal test (NIPT), Horizon, a carrier screening test, and Signatera, a test for cancer recurrence monitoring.
---
NTRA Company Deck
---
NTRA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance for Natera, with significant revenue growth, volume increases across key segments, and positive cash flow. Despite minor challenges such as weather disruptions and some uncertainty in ASP improvements, the company's strategic initiatives in diagnostics and oncology are bearing fruit, leading to an optimistic outlook.Read More>---
NTRA Stock 12 Month Forecast
Average Price Target
$203.23
▲(29.21% Upside)
Technical Analysis
---